ClinicalTrials.gg
RecruitingNCT07322965BRUDYGLAUCOUpdated Jan 14, 2026

Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma

An interventional study of BrudyGlauco and Placebo in Glaucoma, Primary Open Angle Glaucoma (POAG) and Neuroprotection, sponsored by Institut Catala de Retina. Recruiting at 2 sites in Spain. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Primary conditionGlaucoma, Open-AngleRegistry: GlaucomaReclassifiedWhy we changed it
Registry
Glaucoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Glaucoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Institut Catala de Retina · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Glaucoma, Open-Angle with a site in Spain — 6 open to participants now, 9 under way, none of them phase 3. Glaucoma, Open-Angle · Spain.

Planned enrollment
17th of 35
108 · median 107
Started
2025
the only one that year
No phase
18 of 47
4 open now
Registered
46th of 47
by date
Lead sponsor
2 of 47
Institut Catala de Retina

Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, this one is the 17th largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2025, is one of 18 with no phase, and was the 46th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

6 of the 47 studies in Glaucoma, Open-Angle with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Glaucoma, Open-Angle with a site in Spain, or all of them as a file.
02

Study summary

This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial.

This is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence.

The trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function.

The results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.

Read the detailed description

This study investigates the potential neuroprotective or neuromodulatory effects of BrudyGlauco, a nutritional supplement containing docosahexaenoic acid (DHA) and citicoline, in patients with glaucoma. Glaucoma is a progressive optic neuropathy that leads to visual field deterioration and, in severe cases, to blindness. Although current treatments primarily target intraocular pressure (IOP), the progression of vision loss in glaucoma could benefit by therapies aimed at protecting the optic nerve.

This randomized, double-blind, placebo-controlled trial will assess the effects of BrudyGlauco on visual function over 12 months, with the primary outcome focusing on changes in visual field function. Secondary outcomes include treatment safety, tolerance, and the persistence of any observed effects after treatment discontinuation.

Participants will be recruited from Institut Català de Retina (ICR) and Hospital de la Esperanza, where they will undergo regular ophthalmologic evaluations. These evaluations include visual field tests to measure any changes in vision and DHA biomarker analysis using the Dry Blood Spot (DBS) method to assess DHA levels in erythrocyte membranes.

An interim analysis at six months will allow for an early assessment of efficacy and safety. The final results will determine whether BrudyGlauco has neuroprotective potential for glaucoma management, offering insights into its ability to protect the optic nerve and potentially improve quality of life for patients living with the disease.

Glaucoma is one of the leading causes of blindness worldwide, and current treatments that focus on lowering IOP are not always sufficient to prevent the progressive loss of vision. This study will explore whether DHA and citicoline, known for their neuroprotective properties, can offer additional benefits beyond traditional treatments.

03

Conditions studied

  • Glaucoma
  • Primary Open Angle Glaucoma (POAG)
  • Neuroprotection

Browse trials for

Keywords

  • glaucoma
  • Primary Open-Angle Glaucoma (POAG)
  • Neuroprotection
  • Visual Field
  • DHA (Docosahexaenoic Acid)
  • Citicoline
  • Nutritional Supplement
  • Clinical Trial
  • Randomized Controlled Trial (RCT)
  • Visual Function
04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's planned enrollment of 108 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Institut Catala de Retina is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glaucoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with chronic glaucoma (primary or secondary, open-angle or closed-angle) diagnosed in at least one eye, meeting the following criteria:

    Structural damage: Thinning of the neuroretinal rim, peripapillary hemorrhage, or reduction in the nerve fiber layer, confirmed by OCT or color fundus photography.

    Functional damage: At least 3 contiguous abnormal points outside the 95% confidence limit in the pattern deviation map of the visual field.

  2. At least 4 reliable visual field (VF) tests before study enrollment.
  3. Age between 50 and 75 years.
  4. If both eyes meet the inclusion criteria, the eye with the worst Mean Deviation (MD) will be selected as the study eye.

Exclusion criteria

Exclusion Criteria:

  1. Use of any vitamin or nutraceutical supplement in the month prior to screening.
  2. Any condition that could alter visual field testing, including:

    Neurological diseases. Retinal diseases. Advanced cataracts. Treatment with Lyrica (Pregabalin) due to its effect on visual fields.

  3. to acetylsalicylic acid (aspirin) (cross-reactivity risk with citicoline).
  4. Ocular surgery or laser treatment in the 3 months prior to enrollment or planned during the study.
  5. Mean Deviation (MD) of the visual field worse than -20 dB or better than -3 dB.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    BrudyGlauco

    Participants receive BrudyGlauco (DHA + Citicoline) orally, taking two capsules at lunchtime for 12 months.

    Dietary Supplement: BrudyGlauco

  • Placebo comparator
    Placebo Group

    Participants receive placebo (sunflower oil capsules) orally, taking two capsules at lunchtime for 12 months.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementBrudyGlauco

    Participants in the experimental group will receive BrudyGlauco, a dietary supplement containing docosahexaenoic acid (DHA) and citicoline.

  • Dietary supplementPlacebo

    Participants in the placebo comparator group will receive identical-looking capsules containing sunflower oil.

07

What researchers measure

Primary outcomes

  1. Change from baseline in visual function assessed by Mean Deviation (MD) at 12 months

    Change from baseline in visual function assessed by Mean Deviation (MD) at 12 months

    Time frame: 12 months

  2. Change from baseline in visual function assessed by Visual Field Index (VFI) at 12 months

    Change from baseline in visual function assessed by Visual Field Index (VFI) at 12 months

    Time frame: 12 months

Secondary outcomes

  1. Rate of change (slope) in Visual Field Index (VFI) before, during, and after treatment

    Rate of change (slope) in Visual Field Index (VFI) before, during, and after treatment

    Time frame: Baseline, 6 months, 12 months, and 3 months post-treatment (15 months total)

  2. Rate of change (slope) in Mean Deviation (MD) before, during, and after treatment

    Rate of change (slope) in Mean Deviation (MD) before, during, and after treatment

    Time frame: Baseline, 6 months, 12 months, and 3 months post-treatment (15 months total).

  3. Incidence of treatment-emergent adverse events during BrudyGlauco treatment

    Incidence of treatment-emergent adverse events during BrudyGlauco treatment

    Time frame: 12 months

  4. Change from baseline in Visual Field Index (VFI) at 6 months

    Change from baseline in Visual Field Index (VFI) at 6 months

    Time frame: 6 months

  5. Incidence of adverse events at 6 months

    Incidence of adverse events at 6 months

    Time frame: 6 months

  6. Change in Mean Deviation (MD) 3 months after treatment discontinuation

    Change in Mean Deviation (MD) 3 months after treatment discontinuation

    Time frame: 3 months post-treatment (15 months total).

  7. Change in Visual Field Index (VFI) 3 months after treatment discontinuation

    Change in Visual Field Index (VFI) 3 months after treatment discontinuation

    Time frame: 3 months post-treatment (15 months total).

08

Study locations

1 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 101 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 24 months is below that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Jan 7, 2026
StartActual
Apr 1, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
May 30, 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07322965
Lead sponsor
Institut Catala de Retina
Collaborators
Hospital de la Esperanza
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Apr 1, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Jan 14, 2026

Study contacts

Alfonso Antón Lopez Antón Lopez, Prof MD PhD
Contact
alfonso.anton@icrcat.com
+34 93 4340553 ext. 4002
Estela del Mar Sánchez Sotano, Biomedical science
Contact
estela.sanchez@icrcat.com
93 253 16 47

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion